Patents by Inventor Melissa Thomas
Melissa Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139456Abstract: FIGS. 1-16D & 66A-92D disclose a large variety of methods of forming the headgear for use in combination with a breathing apparatus including a unitary plastic core within textile casings. In some configurations, the plastic core material penetrates or bursts-through the textile casing of the straps. Some configurations include over moulding, alignment posts, T-joints and joint housings with injection aperture. FIGS. 17-65 & 93A-94C disclose a large variety of different headgear arrangements including top strap, front strap, rear strap and pairs of straps extending from the mask above and below the ear to meet behind the ear. FIGS. 95-121B disclose a large variety of connectors connecting the headgear assembly to the mask assembly where the headgear, mask and connector form a closed loop when the connector is disengaged with the mask assembly.Type: ApplicationFiled: November 14, 2023Publication date: May 2, 2024Inventors: Paul Mathew Freestone, Janine Elizabeth Collins, Ryan Anthony Graham, Vitaly Kapelevich, Melissa Catherine Bornholdt, Sophie Kathryn Randles, Silas Sao Jin Siew, Steve Thomas, Ronan Leahy, Max Leon Betteridge, Callum Ross Gordon, Vicky Dan Gao, Cameron Robert Willis
-
Patent number: 11972860Abstract: A healthcare charge capture and prioritization system for assisting healthcare providers with capturing their procedures and prioritizing code selection for claim submission is presented. The system can analyze healthcare claim-related data for ranking and ordering Current Procedural Technology (CPT) and International Statistical Classification of Diseases and Related Health Problems (ICD) codes to reduce the utilization of additional processing resources and network utilization from repeated system denials. Additionally, the present disclosure can generate and track analytics relevant to a patient encounters and provider action. It is an object of the invention to provide a system for processing and managing patient interactions, processing and managing healthcare-related charge entry, processing and prioritizing healthcare-related procedure technology codes, and processing and prioritizing disease and related health problem codes.Type: GrantFiled: January 15, 2020Date of Patent: April 30, 2024Assignee: DPACC Administrative Services, LLCInventors: Tung Tran, Shibu Thomas, Amit Mann, Melissa Stewart, Leia Oh-Spradling, Stephanie Fargo
-
Publication number: 20210262038Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: ApplicationFiled: February 5, 2021Publication date: August 26, 2021Inventors: Lawrence Charles LAPOINTE, Susanne K. PEDERSEN, Rohan Kartin BAKER, Snigdha GAUR, Melissa THOMAS
-
Publication number: 20210254169Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: ApplicationFiled: February 5, 2021Publication date: August 19, 2021Inventors: Lawrence Charles LAPOINTE, Susanne K. PEDERSEN, Rohan Kartin BAKER, Snigdha GAUR, Melissa THOMAS
-
Publication number: 20210163621Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.Type: ApplicationFiled: April 10, 2019Publication date: June 3, 2021Applicants: AMGEN INC., KiTe Pharma, Inc.Inventors: Michael John Giffin, Melissa THOMAS, Christopher MURAWSKY, Ryan B. CASE, Lawren WU, Jed J. WILTZIUS, Ruben Alvarez RODRIGUEZ, Jun FENG
-
Patent number: 10941449Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: GrantFiled: May 17, 2013Date of Patent: March 9, 2021Assignee: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence Charles Lapointe, Susanne K. Pedersen, Rohan Baker, Snigdha Gaur, Melissa Thomas
-
Publication number: 20150152505Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: ApplicationFiled: May 17, 2013Publication date: June 4, 2015Applicant: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence Charles Lapointe, Susanne K. Pedersen, Rohan Baker, Snigdha Gaur, Melissa Thomas
-
Publication number: 20070128176Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 22, 2006Publication date: June 7, 2007Inventors: Joel Habener, Henryk Zulewski, Melissa Thomas, Elizabeth Abraham, Mario Vallejo, Colin Leech, Anna Nolan, Andreas Lechner
-
Publication number: 20070071730Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: April 24, 2006Publication date: March 29, 2007Inventors: Joel Habener, Henryk Zulewski, Elizabeth Abraham, Melissa Thomas, Mario Vallejo
-
Publication number: 20060222647Abstract: The present invention provides agents such as agonists, antibodies, antagonists or inhibitors to modulate the activity of PDE5 proteins. These compositions and methods are useful for the diagnosis or treatment of conditions associated with the presence, the deficiency, altered levels, or altered activity of PDE5 proteins.Type: ApplicationFiled: January 28, 2003Publication date: October 5, 2006Inventors: Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Linda McAllister-Lucas, Kate Loughney, William Sonnenburg, Melissa Thomas, Sergei Rybalkin
-
Publication number: 20060216809Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: December 21, 2005Publication date: September 28, 2006Applicants: ICOS CORPORATIONInventors: Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Kate Loughney, Linda McAllister-Lucas, William Sonnenburg, Melissa Thomas
-
Publication number: 20060063700Abstract: The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.Type: ApplicationFiled: April 14, 2005Publication date: March 23, 2006Inventors: Joel Habener, Melissa Thomas
-
Publication number: 20060062769Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 19, 2005Publication date: March 23, 2006Inventors: Joel Habener, Hendrik Zulewski, Elizabeth Abraham, Mario Vallejo, Denise Faustman, Melissa Thomas
-
Publication number: 20050244386Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: November 9, 2004Publication date: November 3, 2005Inventors: Joel Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise Faustman, Melissa Thomas
-
Publication number: 20050196833Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding. cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: January 28, 2003Publication date: September 8, 2005Inventors: Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Linda McAllister-Lucas, Kate Loughney, William Sonnenburg, Melissa Thomas